Key Takeaways
- • CORE Biomedicine, a Boston-based precision oncology company founded by former H3 Biomedicine leaders, completed a $21 million Series A financing round.
- • The round is co-led by UTokyo Innovation Platform Co., Ltd. and Elikon Venture, with participation from eight additional investors including Mitsubishi UFJ Capital, CD Capital, and Root Venture Partners.
- • The company's lineage-based therapeutic approach targets core biological pathways that define cancer cell identity, positioning it to identify drivers beyond genomics and expand addressable patient populations.
- • CORE's platform is designed to enable discovery of first- and best-in-class precision oncology therapies by moving beyond traditional genomic-focused approaches to cancer treatment.
Summary
CORE Biomedicine announced the completion of a $21 million Series A financing round on July 28, 2026, marking a significant capital milestone for the Boston-based precision oncology company. The round is co-led by UTokyo Innovation Platform Co., Ltd. and Elikon Venture, with additional investment from InnoPinnacle Fund, Mitsubishi UFJ Capital Co., Ltd., Suzhou Capital Group Co., Ltd., CD Capital, YuanBio Venture Capital, Vision Incubate Co., Ltd., and Root Venture Partners. The diverse investor base reflects both Asia-Pacific and North American institutional interest in the company's platform technology.
CORE Biomedicine was founded by former leaders of H3 Biomedicine and is developing what the company characterizes as next-generation precision medicines built on a lineage-based therapeutic approach. Rather than relying exclusively on genomic profiling, the company's methodology targets core biological pathways that define cancer cell identity. This approach is designed to identify and target core oncology drivers with precision while simultaneously expanding the potential patient populations that may benefit from resulting therapies—a significant commercial advantage in oncology development where addressing larger addressable markets can improve commercial viability.
The lineage-based platform represents a differentiated approach within the precision oncology space, positioning CORE to discover first- and best-in-class therapies by moving beyond conventional genomics-focused methodologies. The capital raise will support further development and advancement of the company's therapeutic pipeline focused on leveraging this novel precision oncology framework.
CORE Biomedicine was founded by former leaders of H3 Biomedicine and is developing what the company characterizes as next-generation precision medicines built on a lineage-based therapeutic approach. Rather than relying exclusively on genomic profiling, the company's methodology targets core biological pathways that define cancer cell identity. This approach is designed to identify and target core oncology drivers with precision while simultaneously expanding the potential patient populations that may benefit from resulting therapies—a significant commercial advantage in oncology development where addressing larger addressable markets can improve commercial viability.
The lineage-based platform represents a differentiated approach within the precision oncology space, positioning CORE to discover first- and best-in-class therapies by moving beyond conventional genomics-focused methodologies. The capital raise will support further development and advancement of the company's therapeutic pipeline focused on leveraging this novel precision oncology framework.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.